Observational studyThe European journal of health economics : HEPAC : health economics in prevention and care2020
Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
Observational study in The European journal of health economics : HEPAC : health economics in prevention and care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Long-term follow-up and outcomes of a Diabetic Eye Screening Programme in patients aged 80 with no diabetic eye disease at baseline: should we be routinely screening this cohort?Eye (London, England) · 2026Article
- Proliferative Diabetic Retinopathy in Young-Onset Type 1 Diabetes in Croatia: Risk Factors and a Predictive Economic Model for National Screening.Medicina (Kaunas, Lithuania) · 2025Article
- A simple score-based strategy to improve equity of the UK biennial diabetic eye screening protocol among people deemed as low risk.Diabetologia · 2025Article
- Extending the diabetic retinopathy screening intervals in Singapore: methodology and preliminary findings of a cohort study.BMC public health · 2024Article
- Review
- Two-year recall for people with no diabetic retinopathy: a multi-ethnic population-based retrospective cohort study using real-world data to quantify the effect.The British journal of ophthalmology · 2023Article
- Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.PloS one · 2023Article
- Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China.The Lancet regional health. Western Pacific · 2022Article
- Cost-effectiveness of artificial intelligence screening for diabetic retinopathy in rural China.BMC health services research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveExamine the health and economic impact of extending screening intervals in people with Type 2 diabetes (T2DM) and Type 1 diabetes (T1DM) without diabetes-related retinopathy (DR).
settingDiabetic Eye Screening Wales (DESW). STUDY
designRetrospective observational study with cost-utility analysis (CUA) and Decremental Cost-Effectiveness Ratios (DCER) study.
interventionBiennial screening versus usual care (annual screening). INPUTS: Anonymised data from DESW were linked to primary care data for people with two prior screening events with no DR. Transition probabilities for progression to DR were estimated based on a subset of 26,812 and 1232 people with T2DM and T1DM, respectively. DCER above £20,000 per QALY was considered cost-effective.
resultsThe base case analysis DCER results of £71,243 and £23,446 per QALY for T2DM and T1DM respectively at a 3.5% discount rate and £56,822 and £14,221 respectively when discounted at 1.5%. Diabetes management represented by the mean HbA SENSITIVITY ANALYSIS: Extending screening to biennial based on HbA
conclusionsBase case and sensitivity analyses indicate biennial screening to be cost-effective for T2DM irrespective of HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.